DDInter122 DDInter1480
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pitolisant was comparable to that of [modafinil]. Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms ; however, the safety of use in adolescent or paediatric patients have not been established with pitolisant. Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 for the treatment of narcolepsy with or without cataplexy. FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults.
Pitolisant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Pitolisant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Pitolisant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Pitolisant {u} may lead to a major life threatening interaction when taken with {v} Pasireotide
Pitolisant {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Pitolisant may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Pitolisant may lead to a major life threatening interaction when taken with Pasireotide
Pitolisant may lead to a major life threatening interaction when taken with Ribociclib